SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Disclose 15% Stake in Crinetics Pharmaceuticals

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a 15.0% beneficial ownership stake in Crinetics Pharmaceuticals Inc. as of March 31, 2025.

Summary

• FMR LLC and Abigail P. Johnson collectively reported beneficial ownership of 13,957,268.98 shares of Crinetics Pharmaceuticals Inc. common stock.
• This ownership represents 15.0% of the total outstanding common stock of Crinetics Pharmaceuticals Inc.
• The filing is an Amendment No. 3 to Schedule 13G, indicating a passive investment not intended to change or influence control of the issuer.
• The date of the event requiring this filing was March 31, 2025.
• FMR LLC holds sole voting power over 13,955,017.00 shares and sole dispositive power over 13,957,268.98 shares.
• Abigail P. Johnson holds sole dispositive power over 13,957,268.98 shares, with no sole or shared voting power.
• Several FMR LLC subsidiaries and affiliates, including Fidelity Management & Research Company LLC, are listed as entities that beneficially own shares, with Fidelity Management & Research Company LLC owning 5% or greater of the outstanding shares.

Sentiment

Score: 7

Explanation: The filing indicates a significant, passive institutional investment by FMR LLC and Abigail P. Johnson, which can be viewed positively as a vote of confidence in Crinetics Pharmaceuticals Inc. However, as a passive filing, it offers no direct operational or financial insights into the issuer.

Positives

• The disclosure of a significant 15.0% stake by a major institutional investor like FMR LLC and its affiliates can be viewed as a vote of confidence in Crinetics Pharmaceuticals Inc.

Future Outlook

The document, a Schedule 13G, is a disclosure of beneficial ownership and does not contain forward-looking statements or guidance regarding the issuer's future performance or outlook.

Industry Context

This filing is a standard disclosure of institutional ownership and does not provide specific analysis of broader industry trends or competitors for Crinetics Pharmaceuticals Inc.

Related Party Transactions

• Members of the Johnson family, including Abigail P. Johnson, are the predominant owners (49% voting power) of Series B voting common shares of FMR LLC, and have a shareholders' voting agreement to vote in accordance with the majority, potentially forming a controlling group with respect to FMR LLC under the Investment Company Act of 1940.

Stakeholder Impact

• Shareholders may view the significant institutional investment by FMR LLC as a positive signal, potentially increasing investor confidence and market stability for Crinetics Pharmaceuticals Inc.

Key Dates

Keywords

Crinetics Pharmaceuticals, FMR LLC, Abigail P. Johnson, Schedule 13G, beneficial ownership, institutional investment, common stock, pharmaceuticals, biotechnology